Jaclyn Neely

9.1k total citations · 4 hit papers
42 papers, 2.1k citations indexed

About

Jaclyn Neely is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jaclyn Neely has authored 42 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 26 papers in Hepatology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jaclyn Neely's work include Cancer Immunotherapy and Biomarkers (38 papers), Hepatocellular Carcinoma Treatment and Prognosis (26 papers) and Ferroptosis and cancer prognosis (12 papers). Jaclyn Neely is often cited by papers focused on Cancer Immunotherapy and Biomarkers (38 papers), Hepatocellular Carcinoma Treatment and Prognosis (26 papers) and Ferroptosis and cancer prognosis (12 papers). Jaclyn Neely collaborates with scholars based in United States, Spain and Japan. Jaclyn Neely's co-authors include Bruno Sangro, Ignacio Melero, Thomas Yau, Anthony B. El-Khoueiry, Masatoshi Kudo, Su Pin Choo, Ann‐Lii Cheng, Richard S. Finn, Yun Shen and Marina Tschaika and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Cancer Research.

In The Last Decade

Jaclyn Neely

41 papers receiving 2.0k citations

Hit Papers

CheckMate 459: A randomized, multi-center phase III study... 2016 2026 2019 2022 2019 2016 2020 2021 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
    2019 497 citations Thomas Yau, Richard S. Finn et al. Annals of Oncology profile →
  2. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
    2016 281 citations Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research profile →
  3. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
    2020 274 citations Bruno Sangro, Ignacio Melero et al. Journal of Hepatology profile →
  4. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
    2021 141 citations Masatoshi Kudo, Ana Matilla et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jaclyn Neely United States 18 1.3k 1.2k 587 417 391 42 2.1k
Leonid Dubrovsky United States 12 828 0.6× 858 0.7× 399 0.7× 362 0.9× 272 0.7× 29 1.6k
Yun Shen United States 25 2.2k 1.7× 611 0.5× 848 1.4× 228 0.5× 1.1k 2.9× 46 2.8k
Marina Tschaika United States 15 1.7k 1.3× 534 0.4× 535 0.9× 216 0.5× 678 1.7× 37 2.3k
Lucjan Wyrwicz Poland 11 919 0.7× 385 0.3× 197 0.3× 200 0.5× 683 1.7× 41 1.4k
Cécile Charpy France 13 661 0.5× 287 0.2× 357 0.6× 139 0.3× 262 0.7× 29 1.2k
Sebastian Leibl Austria 17 475 0.4× 272 0.2× 195 0.3× 328 0.8× 194 0.5× 29 1.3k
Stacey Stein United States 18 802 0.6× 355 0.3× 108 0.2× 167 0.4× 387 1.0× 74 1.4k
Christoph Mancao United States 15 867 0.7× 131 0.1× 312 0.5× 396 0.9× 221 0.6× 42 1.2k
Maria Chiara Tronconi Italy 17 1.1k 0.8× 277 0.2× 79 0.1× 157 0.4× 370 0.9× 44 1.4k
Hui-Qiang Huang China 22 819 0.6× 90 0.1× 451 0.8× 740 1.8× 139 0.4× 51 1.4k

Countries citing papers authored by Jaclyn Neely

Since Specialization
Citations

This map shows the geographic impact of Jaclyn Neely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaclyn Neely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaclyn Neely more than expected).

Fields of papers citing papers by Jaclyn Neely

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaclyn Neely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaclyn Neely. The network helps show where Jaclyn Neely may publish in the future.

Co-authorship network of co-authors of Jaclyn Neely

This figure shows the co-authorship network connecting the top 25 collaborators of Jaclyn Neely. A scholar is included among the top collaborators of Jaclyn Neely based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaclyn Neely. Jaclyn Neely is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luke, Jason J., Katherine M. Bever, F. Stephen Hodi, et al.. (2025). Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial. Journal for ImmunoTherapy of Cancer. 13(5). e011170–e011170. 2 indexed citations
2.
Khushalani, Nikhil I., Patrick A. Ott, Robert L. Ferris, et al.. (2024). Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 12(3). e007364–e007364. 18 indexed citations
3.
El-Khoueiry, Anthony B., Jörg Trojan, Tim Meyer, et al.. (2023). Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Annals of Oncology. 35(4). 381–391. 27 indexed citations
4.
Yau, Thomas, Vittorina Zagonel, Armando Santoro, et al.. (2022). Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial. Journal of Clinical Oncology. 41(9). 1747–1757. 46 indexed citations
5.
6.
Kudo, Masatoshi, Ana Matilla, Armando Santoro, et al.. (2021). CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. Journal of Hepatology. 75(3). 600–609. 141 indexed citations breakdown →
7.
Yau, Thomas, Chih‐Hung Hsu, Yoon‐Koo Kang, et al.. (2020). O-5 Efficacy and safety of nivolumab + ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study. Annals of Oncology. 31. 233–233. 2 indexed citations
8.
Sangro, Bruno, Ignacio Melero, Samir Wadhawan, et al.. (2020). Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. Journal of Hepatology. 73(6). 1460–1469. 274 indexed citations breakdown →
9.
Sangro, Bruno, Richard S. Finn, Ann‐Lii Cheng, et al.. (2020). LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. Annals of Oncology. 31. S241–S242. 42 indexed citations
10.
Yau, Thomas, Richard S. Finn, Ann‐Lii Cheng, et al.. (2019). CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Annals of Oncology. 30. v874–v875. 497 indexed citations breakdown →
11.
Yau, Thomas, Yoon‐Koo Kang, Tae‐You Kim, et al.. (2019). Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. Journal of Clinical Oncology. 37(15_suppl). 4012–4012. 178 indexed citations
12.
Kudo, Masatoshi, Ana Matilla, Armando Santoro, et al.. (2019). Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. Journal of Clinical Oncology. 37(4_suppl). 327–327. 79 indexed citations
13.
Sangro, Bruno, Ignacio Melero, Chiun Hsu, et al.. (2017). Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040. UCL Discovery (University College London). 12 indexed citations
14.
Crocenzi, Todd S., Anthony B. El-Khoueiry, Thomas Cheung Yau, et al.. (2017). Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. Journal of Clinical Oncology. 35(15_suppl). 4013–4013. 68 indexed citations
15.
Segal, Neil H., Theodore F. Logan, F. Stephen Hodi, et al.. (2016). Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. Clinical Cancer Research. 23(8). 1929–1936. 281 indexed citations breakdown →
16.
Melero, Ignacio, Bruno Sangro, Tung On Yau, et al.. (2016). 219O Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study. Annals of Oncology. 27. ix68–ix69. 4 indexed citations
17.
El-Khoueiry, Anthony B., Bruno Sangro, Thomas Cheung Yau, et al.. (2016). Phase I/II safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of the CheckMate-040 dose escalation study.. Journal of Clinical Oncology. 34(15_suppl). 4012–4012. 24 indexed citations
18.
Sangro, Bruno, Ignacio Melero, Thomas Cheung Yau, et al.. (2016). Safety and antitumor activity of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (HCC): Interim analysis of dose-expansion cohorts from the phase 1/2 CheckMate-040 study.. Journal of Clinical Oncology. 34(15_suppl). 4078–4078. 31 indexed citations
19.
Melero, Ignacio, Bruno Sangro, Thomas Yau, et al.. (2016). Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study. Annals of Oncology. 27. vi209–vi209. 4 indexed citations
20.
Anning, L, et al.. (2011). Management of young onset colorectal cancer: divergent practice in the East of England. Colorectal Disease. 13(9). e297–302. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonid Dubrovsky Breakdown of academic impact, for papers by Yun Shen Breakdown of academic impact, for papers by Marina Tschaika Breakdown of academic impact, for papers by Lucjan Wyrwicz Breakdown of academic impact, for papers by Cécile Charpy Breakdown of academic impact, for papers by Sebastian Leibl Breakdown of academic impact, for papers by Stacey Stein Breakdown of academic impact, for papers by Christoph Mancao Breakdown of academic impact, for papers by Maria Chiara Tronconi Breakdown of academic impact, for papers by Hui-Qiang Huang
Rankless by CCL
2026